ArticleLife (Basel, Switzerland)2022

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project.

Cristiano Bortoluzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.